Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas-ko ikertzaileekin lankidetzan egindako argitalpenak (22)

2023

  1. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  2. Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact

    Alzheimer's Research and Therapy, Vol. 15, Núm. 1

2022

  1. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 7, pp. 1037-1049

  2. Long runs of homozygosity are associated with Alzheimer’s disease

    Translational Psychiatry, Vol. 11, Núm. 1

2019

  1. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*

    Molecular and Cellular Proteomics, Vol. 18, Núm. 3, pp. 546-560

  2. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity

    Cortex, Vol. 121, pp. 117-124

  3. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

    Alzheimer's and Dementia, Vol. 15, Núm. 10, pp. 1333-1347

  4. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753

  5. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: A cross-sectional analysis from the AB255 Study

    Alzheimer's Research and Therapy, Vol. 11, Núm. 1

  6. Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels

    Journal of Alzheimer's Disease, Vol. 70, Núm. 1, pp. 211-225

2018

  1. Cortical microstructural changes along the Alzheimer's disease continuum

    Alzheimer's and Dementia, Vol. 14, Núm. 3, pp. 340-351

2017

  1. Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum

    Neurobiology of Aging, Vol. 53, pp. 192.e1-192.e4

  2. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

2016

  1. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

    Alzheimer's and Dementia, Vol. 12, Núm. 2, pp. 154-163

2015

  1. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

    Neurology, Vol. 85, Núm. 7, pp. 626-633

2014

  1. Diet, cognition, and Alzheimer's disease: Food for thought

    European Journal of Nutrition, Vol. 53, Núm. 1, pp. 1-23

  2. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: A multicenter study in Spain

    Journal of Alzheimer's Disease, Vol. 39, Núm. 4, pp. 719-726

2012

  1. The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease

    European Journal of Neurology, Vol. 19, Núm. 8, pp. 1100-1107

2010

  1. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP

    Neurobiology of Aging, Vol. 31, Núm. 5, pp. 725-731